Simplify Managed Futures Strategy ETF CTA 深 滬
等待開盤 07-26 09:30:00 美东时间
28.08
-0.210
-0.74%
華盛通- 最 高28.21
- 今 開28.21
- 成交量 30.58万股
- 最 低 27.94
- 昨 收 28.29
- 總市值 10.95亿
- 52周最高 29.843
- 市盈率 靜 --
- 換手率 0.78%
- 52周最低 24.3568
- 委 比 0.00%
- 總股本 3900.00万
- 歷史最高 29.843
- 量 比 0.57
- 振 幅 0.95%
- 歷史最低 18.6867
- 每 手 1
- 風險率 1.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Stretched sentiment and positioning are downside risks to 2H – HSBC
Market sentiment indicators are now flashing a “sell” signal, suggesting potential downside risk in the latter half of the year, according to Max Kettner, chief multi-asset strategist at HSBC Global R...
07-22 00:40
480亿美元算法洪峰来袭! 快钱涌入之势有望带动美股新一轮“融涨”
系统性基金准备向美国股市投入480亿美元。摩根大通美国股票衍生品策略主管布拉姆·卡普兰表示，波动控制基金是仍在寻求向股市注入现金的系统性基金之一。
07-16 19:11
Precision Biosciences Announced dditional Preclinical Data For PBGENE-DMD, In Vivo Gene Editing Approach For Duchenne Muscular Dystrophy (DMD), Clinical Trial Application Submission Expected In 2025 With Clinical Data Expected In 2026
New preclinical data for the PBGENE-DMD final clinical candidate demonstrates an increase in dystrophin positive muscle cells across key muscle types, potentially driven by editing of muscle satellite cells.PBGENE-DMD is
07-16 19:05
Catenai PLC Announces Successful Equity Issue and GM Resolutions
An update from Catenae Innovation Plc ( ($GB:CTAI) ) is now available. Catenai ...
07-15 22:17
Beyond The Numbers: 14 Analysts Discuss Best Buy Co Stock
Best Buy Co (NYSE:BBY) has been analyzed by 14 analysts in the last three month...
07-14 20:00
Solid Biosciences Receives FDA IND And Health Canada CTA Approval For First-In-Class Cardiac Gene Therapy To Treat Catecholaminergic Polymorphic Ventricular Tachycardia
- SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies -- SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA
07-09 04:08
